Radiofrequency ablation in the management of primary hepatic and biliary tumors.
Publication Title
World J Gastrointest Oncol
Document Type
Article
Publication Date
1-15-2022
Keywords
washington; swedish; swedish dhi; swedish digestive health
Abstract
In the United States, 80%-90% of primary hepatic tumors are hepatocellular carcinomas and 10%-15% are cholangiocarcinomas (CCA), both with high mortality rate, particularly CCA, which portends a worse prognosis. Traditional management with surgery has good outcomes in appropriately selected patients; however, novel ablative treatment options have emerged, such as radiofrequency ablation (RFA), which can improve the prognosis of both hepatic and biliary tumors. RFA is aimed to generate an area of necrosis within the targeted tissue by applying thermal therapy via an electrode, with a goal to completely eradicate the tumor while preserving surrounding healthy tissue. Role of RFA in management of hepatic and biliary tumors forms the focus of our current mini-review article.
Keywords: Biliary tumor; Cholangiocarcinoma; Cholangiocarcinomas; Hepatic tumor; Hepatocellular carcinoma; Hepatocellular carcinomas; Radiofrequency ablation
Area of Special Interest
Digestive Health
Area of Special Interest
Kidney & Diabetes
Area of Special Interest
Cancer
Specialty/Research Institute
Gastroenterology
Specialty/Research Institute
Endocrinology
Specialty/Research Institute
Oncology
